Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer DiagnosticsZacks Investment Research • 06/17/25
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)Business Wire • 06/15/25
Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025Business Wire • 06/15/25
Phase 3 Data for Incyte's Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The LancetBusiness Wire • 06/12/25
Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025Business Wire • 06/03/25
Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United StatesBusiness Wire • 05/15/25
20 stocks of companies showing excellent earnings-season trends even as the economy coolsMarket Watch • 05/12/25
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product SalesZacks Investment Research • 04/29/25
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 04/29/25
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025Business Wire • 04/25/25
Incyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 04/23/25
Incyte Gears Up to Report Q1 Earnings: Here's What You Should KnowZacks Investment Research • 04/23/25